897445-45-3

Usage

Uses

Used in Pharmaceutical Synthesis:
4-Chloro-6-(4-chloro-phenyl)-pyrimidine is used as an intermediate in the synthesis of pharmaceuticals for its potential biological activities.
Used in Agrochemical Synthesis:
4-Chloro-6-(4-chloro-phenyl)-pyrimidine is also utilized as a building block in the creation of agrochemicals, contributing to advancements in agriculture.
Used in Cancer Research:
4-Chloro-6-(4-chloro-phenyl)-pyrimidine is studied for its potential as an anti-cancer agent, indicating its use in medical research for developing treatments against cancer.
Used in Protein Kinase Inhibition:
It has been investigated for its role as an inhibitor of protein kinase C, which suggests its application in the study and modulation of cellular signaling pathways related to various diseases.
Overall, 4-Chloro-6-(4-chloro-phenyl)-pyrimidine is a significant compound with applications in both the medical and agricultural sectors, as well as in the synthesis of various organic compounds.

Upstream product

• 3934-20-1 2,6-Dichloropyrimidine 
• 1679-18-1 4-Chlorophenylboronic acid 
• 1193-21-1 4,6-dichloropyrimidine 

Downstream Products

• 1368563-96-5 6-(4-chloro-phenyl)-pyrimidine-4-carboxylic acid 
• 917396-05-5 4-(4-chlorophenyl)-6-hydrazinylpyrimidine 

Relevant academic research and scientific papers

Synthesis of novel substituted pyrimidine derivatives bearing a sulfamide group and their in vitro cancer growth inhibition activity

The synthesis of two series of novel substituted pyrimidine derivatives bearing a sulfamide group have been described and their in vitro cancer growth inhibition activities have been evaluated against three human tumour cell lines (HT-29, M21, and MCF7). In general, growth inhibition activity has been enhanced by the introduction of a bulky substituent on the aromatic ring with the best compound having GI50??6?μM for all the human tumour cell lines. The MCF7 selective compounds were evaluated on four additional human invasive breast ductal carcinoma cell lines (MDA-MB-231, MDA-MB-468, SKBR3, and T47D) and were selective against T47D cell line in all cases except one, suggesting a potential antiestrogen activity.

Synthesis, characterization, and molecular docking for anti-inflammatory activity of 4-(4-chlorophenyl)-6-aryloxypyrimidines

Some aryloxypyrimidine derivatives have been synthesized by reaction of 4-chloro-6-(4-chlorophenyl)pyrimidine (2) and phenols. Structures of the newly synthesized compounds have been established on the basis of their 1H-nuclear magnetic resonan

Computational design and discovery of nanomolar inhibitors of IκB kinase β

IκB kinase β (IKKβ) is a useful target for the discovery of new medicines for cancer and inflammatory diseases. In this study, we aimed to identify new classes of potent IKKβ inhibitors based on structure-based virtual screening, de novo design, and chemical synthesis. To increase the probability of finding actual inhibitors, we improved the scoring function for the estimation of the IKKβ-inhibitor binding affinity by introducing proper solvation free energy and conformational destabilization energy terms for putative inhibitors. Using this modified scoring function, we have been able to identify 15 submicromolar-level IKKβ inhibitors that possess the phenyl-(4-phenyl-pyrimidin-2-yl)-amine moiety as the molecular core. Decomposition analysis of the calculated binding free energies showed that a high biochemical potency could be achieved by lowering the desolvation cost and the conformational destabilization for the inhibitor required for binding to IKKβ as well as by strengthening the interactions in the ATP-binding site. The formation of two hydrogen bonds with backbone amide groups of Cys99 in the hinge region was found to be necessary for tight binding of the inhibitors in the ATP-binding site. From molecular dynamics simulations of IKKβ-inhibitor complexes, we also found that complete dynamic stability of the bidentate hydrogen bond with Cys99 was required for low nanomolar-level inhibitory activity. This implies that the scoring function for virtual screening and de novo design would be further optimized by introducing an additional energy term to measure the dynamic stability of the key interactions in enzyme-inhibitor complexes.

Development of a series of aryl pyrimidine kynurenine monooxygenase inhibitors as potential therapeutic agents for the treatment of Huntingtons disease

We report on the development of a series of pyrimidine carboxylic acids that are potent and selective inhibitors of kynurenine monooxygenase and competitive for kynurenine. We describe the SAR for this novel series and report on their inhibition of KMO activity in biochemical and cellular assays and their selectivity against other kynurenine pathway enzymes. We describe the optimization process that led to the identification of a program lead compound with a suitable ADME/PK profile for therapeutic development. We demonstrate that systemic inhibition of KMO in vivo with this lead compound provides pharmacodynamic evidence for modulation of kynurenine pathway metabolites both in the periphery and in the central nervous system.

(3R,4S)-4-(2,4,5-Trifluorophenyl)-pyrrolidin-3-ylamine inhibitors of dipeptidyl peptidase IV: Synthesis, in vitro, in vivo, and X-ray crystallographic characterization

A series of pyrrolidine based inhibitors of dipeptidyl peptidase IV were developed from a high throughput screening hit for the treatment of type 2 diabetes. Potency, selectivity, and pharmacokinetic properties were optimized resulting in the identification of a pre-clinical candidate for further profiling.

Triazolopyrimidine cannabinoid receptor 1 antagonists

The present application describes compounds according to both Formulas I and II, pharmaceutical compositions comprising at least one compound according to either Formula I or II and optionally one or more additional therapeutic agents, and methods of treatment using the compounds according to Formulas I and II both alone and in combination with one or more additional therapeutic agents. The compounds have the following general formulas: including all prodrugs, solvates, pharmaceutically acceptable salts and stereoisomers, wherein R1, R2, R3, R4 and R5 are described herein.

COMPOUNDS USEFUL AS CHEMOKINE RECEPTOR ANTAGONISTS

The present invention relates to compounds useful as Chemokine Receptor antagonists. Compounds of general formula I are provided: or pharmaceutically acceptable salts thereof. The invention also provides pharmaceutically acceptable compositions comprising said compounds and methods of using the compounds and compositions for the inhibition of Chemokine Receptors and also for the treatment of various diseases, conditions, or disorders, including acute or chronic inflammatory disease, cancer or osteolytic bone disorders.